Silence Therapeutics plc

Regulatory Filings • Jun 4, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8062I

Silence Therapeutics PLC

04 June 2014

4 June 2014

Silence Therapeutics plc

Notice of General Meeting and posting of Annual Report

Silence Therapeutics plc, AIM: SLN ('Silence' or 'the Company'), a leading international RNA therapeutics company, will be holding its annual General Meeting on Friday, 27 June 2014 at 2pm at Silence Therapeutics, 1 Lyric Square, London, W6 0NB.

The Annual Report has today been posted to shareholders and can also be viewed online at: http://silence-therapeutics.com/investor-relations/reports-and-disclosures/.

Enquiries:

Silence Therapeutics plc	+44 (0)20 3700 9711
Tim Freeborn, Finance Director & Company Secretary
Rozi Morris, Communications Manager
Canaccord Genuity Limited	+44 (0)20 7523 8350
Lucy Tilley/Dr Julian Feneley/Henry Fitzgerald-O'Connor

About Silence Therapeutics plc    (www.silence-therapeutics.com)

Silence Therapeutics is a leading RNAi (RNA interference) therapeutics platform technology company which has proprietary delivery systems. Combined, the RNAi and delivery platforms enable the development of multiple products to multiple drug targets allowing the development of novel therapeutics for diseases with high unmet medical need.

Listed on London's AIM since 2006, Silence is one of only six quoted companies globally with well-validated RNA delivery technology.  It has a robust IP estate, with three Phase II trials already completed (pending results). 

This information is provided by RNS

The company news service from the London Stock Exchange

END

NOASSSSWLFLSEDM